Brief: Arcellx Presents Continued Robust Long-Term Responses From Its CART-DDBCMA Phase 1 Expansion Trial In Patients With Relapsed Or Refractory Multiple Myeloma

Arcellx

03/06/2022 21:03

June 3 (Reuters) - Arcellx Inc  ACLX.O :
    * ARCELLX PRESENTS CONTINUED ROBUST LONG-TERM RESPONSES FROM
ITS
CART-DDBCMA PHASE 1 EXPANSION TRIAL IN PATIENTS WITH RELAPSED OR
REFRACTORY MULTIPLE MYELOMA AT THE 2022 ASCO ANNUAL MEETING
    * ARCELLX INC - PHASE 2 PIVOTAL STUDY ON TRACK TO INITIATE
BY YE
2022
    * ARCELLX INC - 100% ORR AT BOTH DOSE LEVELS; DEEP AND
DURABLE
RESPONSES OBSERVED IN PATIENTS WITH POOR PROGNOSTIC FACTORS
    * ARCELLX INC - NO CASES OF GRADE ≥3 CRS AND NO DELAYED
NEUROTOXICITY OR PARKINSONIAN-LIKE EVENTS OBSERVED AT RP2D
(N=25)

Source text for Eikon:  ID:nPnbFdNTpa 
Further company coverage:  ACLX.O